Services on Demand
Journal
Article
Spanish (pdf)
Article in xml format
Article references
Automatic translation
Send this article by e-mailIndicators
Cited by SciELO
Related links
Similars in
SciELO
Share
Permalink
Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
Print version ISSN 2225-5109On-line version ISSN 2227-4731
Abstract
DIAZ-SILVA, Víctor Hugo; DOLORES TAFUR-HOYOS, Brenda Aurora; BURGA-GUEVARA, Diana Katherine and SANCHEZ NEIRA, Carlos. The deferral and relapse time after induction chemotherapy in children with acute lymphoblastic leukemia at a National Hospital in Lambayeque. Rev. Cuerpo Med. HNAAA [online]. 2022, vol.15, n.1, pp.81-85. Epub Mar 31, 2022. ISSN 2225-5109. http://dx.doi.org/10.35434/rcmhnaaa.2022.151.1097.
Objective:
To know the deferral and relapse time after induction chemotherapy in children with acute lymphoblastic leukemia (ALL) in a national hospital in Lambayeque
The study:
Analytical observational study of a retrospective cohort. The medical records of patients aged 2 and 15 years, with diagnosis of ALL, who achieved complete remission at the end of induction, treated in a national hospital in Lambayeque were reviewed.
Findings:
The patients studied had a median age of 5 years. Although the majority responded at the end of IA induction, still 43/75 children with ALL relapsed. Children with relapse had a deferral time of 6 days [IQR: 0-25] between the end of induction and the beginning of the consolidation phase.
Conclusion:
Deferral time ≥7 days in chemotherapy regimens affects the sustainability of remission.
Keywords : Leukemia acute lymphoblastic; Recurrence; Chemotherapy.
